Azer-cel

Phase 1Biologic

IImugene Limited

Azer-cel is one of 52 biologic programs targeting B-cell acute lymphoblastic leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

105 competitors in B-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

8 2

Cytosar

Teva

Phase 3

4 3

Trexall

Alnylam Pharmaceuticals

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 5

Novantrone

Pfizer

Phase 3

1 6

Decadron

AAspen Global Incorporated

Phase 3

5 7

Gleevec

Novartis

Phase 3

—8

Elspar

DDutch Childhood Oncology Group

Phase 3

3 9

Purinethol

SStason

Phase 3

3 10

Oncaspar

SServier

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT03666000

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·IImugene Limited·Phase 1·NCT03666000·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azer-cel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azer-cel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azer-cel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imugene Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IImugene Limited

Azer-cel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

References

Drug Info

Quick Facts

Related News